Biomarker discovery and validation organisations identify, measure and evaluate biological signals that help researchers understand disease and treatment response. Their services support drug development, patient stratification and translational research, using molecular, cellular, imaging or physiological measurements.
This category includes companies working on:
Browse 48 UK biomarker discovery and validation companies below.
Clinical trial delivery for Alzheimer's and neurodegenerative disease
Scottish Brain Sciences is a contract research organisation building and operating clinical trial infrastructure for Alzheimer's disease and other neurodegenerative conditions. Working with pharmaceutical sponsors, it delivers trial screening, patient recruitment, and study conduct at dedicated clinical sites in…
Plasma amino acid biomarkers for multi-cancer risk assessment
Proteotype Diagnostics develops blood tests to support earlier assessment of possible cancer. Its Enlighten test measures patterns of circulating amino acids in plasma and applies machine learning to estimate the likelihood of malignancy across several solid tumour types. It is designed to inform further clinical…
Preclinical and clinical CRO specialising in biomarker services
Epistem is a contract research organisation providing preclinical and clinical research services to pharmaceutical and biotechnology companies. Its capabilities span in vivo and in vitro preclinical models across oncology, gastrointestinal disease, dermatology, and autoimmune indications, alongside GCLP-accredited…
AI-powered infrared diagnostic test for breast cancer recurrence risk
Digistain is a biotechnology company developing MHRA-cleared diagnostic technology for predicting breast cancer recurrence risk. The platform uses infrared spectrometry to generate spectroscopic signatures from tumour biopsy tissue, with AI analysis producing a personalised prognostic score indicating the likelihood…
Contract proteomics CRO and inventor of TMT isobaric mass tags
Proteome Sciences is a contract proteomics organisation and reagent manufacturer specialising in mass spectrometry-based protein biomarker discovery, validation, and targeted assay development. Its proprietary workflows serve pharmaceutical and biotechnology clients across drug discovery and clinical research. The…
Platelet function biomarkers and assays for cardiovascular clinical research
HaemAnalytica is a University of Reading biotechnology spin-out developing platelet-function assays for cardiovascular research and clinical trials. Its TRIPLEcheck platform uses platelet biomarkers to predict thrombotic risk and antiplatelet treatment response. PLANA combines preserved blood samples, flow cytometry…
Coronary plaque biomarkers for precision cardiovascular medicine
PlaqueTec develops a catheter-based liquid biopsy system to investigate biological processes driving coronary artery disease. Its device samples blood at sites around coronary plaques, allowing researchers to compare local concentrations of proteins and other molecules. These data feed its BioCarta platform for…
AI and photonics platform for personalised drug development
iLoF is a digital health company developing an AI-powered platform that uses proprietary photonics technology to generate optical fingerprints from blood samples, building a cloud-based library of biological profiles and biomarkers. The platform enables non-invasive patient stratification and personalised drug…
Non-invasive skin epigenomics platform for clinical and cosmetic research
Mitra Bio is a contract research organisation providing a non-invasive skin epigenomics platform to pharmaceutical and cosmetic companies conducting clinical trials on dermatological and age-reversal interventions. Using tape-strip skin sampling combined with whole-genome DNA methylation sequencing and bioinformatic…
Genetic biomarker discovery platform for precision medicine and diagnostics
Population Bio is a genomic discovery company providing genetic biomarker identification services to pharmaceutical and biotechnology partners. Its platform accelerates the discovery of disease-relevant copy number variants and associated genetic variants, enabling companion diagnostic development, drug repurposing,…
Proteomics and AI liquid biopsy for early lung cancer detection
Oxford Cancer Analytics is a biotechnology company developing blood-based diagnostic tests for early cancer detection using high-throughput circulating proteome analysis and machine learning. Its platform identifies protein biomarker signatures from blood samples to support clinical decision-making in lung disease,…
Multiplexed LC-MS proteomics for biomarker development and clinical trials
Inoviv is a bioanalytical contract research company providing multiplexed, quantitative LC-MS targeted proteomics services to pharmaceutical and biotech clients. Its platform supports biomarker discovery, patient stratification, companion diagnostic development, and treatment efficacy monitoring across clinical and…
Ultrasensitive multiplex biomarker services for clinical studies
Aeirtec is a contract research organisation providing clinical study biomarker measurement services to the biopharma industry. Its patented immobilised-bead immunomultiplex assay technology enables high-sensitivity quantification of protein biomarkers from clinical samples at femtogram concentrations. Services include…
Gut microbiome tests predicting biologic drug response in IBD
AlphaBiomics is a precision medicine company developing diagnostics that analyse the gut microbiome to guide treatment decisions. Its lead test uses a stool sample collected at home and machine learning analysis of microbial sequencing data to predict which patients with inflammatory bowel disease are likely to…
AI-driven neuroimaging analytics for clinical trials
Queen Square Analytics is a UCL spin-out providing advanced neuroimaging data analytics for neurological clinical trials. The company applies machine learning to MRI data for patient stratification, treatment response prediction, and imaging protocol design, with a primary focus on multiple sclerosis and…
Long-read RNA sequencing platform for cancer biomarker discovery and diagnostics
Wobble Genomics is a Scottish biotechnology company developing long-read RNA sequencing technologies for biomarker discovery and cancer diagnostics. Its core platform combines a biochemical method to enrich rare and low-abundance full-length RNA transcripts, with a bioinformatics pipeline for novel transcript…
Non-endoscopic molecular diagnostics for early oesophageal cancer detection
Cyted Health is a gastrointestinal molecular diagnostics company developing minimally invasive testing for early detection and monitoring of oesophageal pre-cancer and cancer. Its platform combines a swallowable capsule sponge cell collection device with AI-driven biomarker molecular assays to detect Barrett's…
NHS-embedded specialist pathology services and clinical biobank access
Novopath is the commercial pathology laboratory of Newcastle upon Tyne Hospitals NHS Foundation Trust, providing specialist tissue-based diagnostic and research services to biopharma, biotech, and academic clients. Services include histopathology, immunohistochemistry, tissue microarray construction, digital…
AI-powered EEG platform for CNS clinical trials
Cumulus Neuroscience is a digital health software company providing an integrated brain monitoring and analytics platform for neuroscience clinical trials. Its platform combines a medical-grade EEG headset with machine learning analytics to generate objective, at-home physiological and cognitive biomarker data.…
Specialist biomarker and bioanalytical CRO for clinical drug development
Synexa Life Sciences is a specialist contract research organisation providing biomarker and bioanalytical laboratory services to global biopharmaceutical companies. The company develops, validates, and delivers custom assays supporting clinical trials and translational studies, with expertise spanning LC-MS/MS…
Benchscope's UK biomarker discovery and validation directory includes specialist CROs, bioanalytical laboratories, biotechnology companies, research facilities and technology developers. Inclusion focuses on substantive biomarker identification, assay development, analytical validation or research measurement services, rather than routine clinical testing or general-purpose reagent supply. A research assay being analytically validated does not necessarily mean it is authorised for clinical diagnosis.